Abstract:Abstract Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the low response rate of α-PD-1/PD-L1 therapy remains to be resolved. For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of the co-stimulatory molecule, stimulator of interferon genes agonists, fecal microbiota transplantation, epigenetic modulators, or metabolic modulators, have superior antitumor efficacies and higher response rates. Moreover, bifunctional or bispecific antibodies containing α-PD-1/PD-L1 moiety also elicited more potent antitumor activity. These combination strategies simultaneously boost multiple processes in cancer-immunity cycle, remove immunosuppressive brakes, and orchestrate an immunosupportive tumor microenvironment. In this review, we summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies. Moreover, we focused on the advances of α-PD-1/PD-L1-based immunomodulatory strategies in clinical studies. Given the heterogeneity across patients and cancer types, individualized combination selection could improve the effects of α-PD-1/PD-L1-based immunomodulatory strategies and relieve treatment resistance.

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Shining Light on Advanced NSCLC in 2017: Combining Immune Checkpoint Inhibitors.

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake

Combination Cancer Immunotherapy Of Nanoparticle-Based Immunogenic Cell Death Inducers And Immune Checkpoint Inhibitors

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Immune Checkpoint Inhibitor-Based Strategies For Synergistic Cancer Therapy

Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Combination strategies to maximize the benefits of cancer immunotherapy

Improvement Strategy for Immune Checkpoint Blockade: A Focus on the Combination with Immunogenic Cell Death Inducers.

Next-generation combination approaches for immune checkpoint therapy

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer

Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy